Cardinal Health raises its fiscal 2026 outlook after third quarter revenue grew 11% and non-GAAP EPS surged 35%.

Cardinal Health reported third quarter fiscal 2026 revenue of $60.9 billion, an 11% year-over-year increase. Non-GAAP diluted earnings per share grew 35% to $3.17, driven by strong performance in the Pharmaceutical segment, which offset weakness in the Medical division.

Key Highlights

• The company raised its full-year fiscal 2026 non-GAAP EPS guidance to a range of $10.70 to $10.80, representing 30% to 31% growth.
• Pharmaceutical and Specialty Solutions segment profit increased 18% to $784 million, driven by growth in brand and specialty products and positive generics performance.
• In contrast, Global Medical Products and Distribution segment profit declined 36% to $25 million, primarily due to the adverse impact of tariffs.
• The company completed an additional $250 million accelerated share repurchase program, bringing the fiscal year-to-date total to $1.0 billion.